Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHRM 864 > E1 association practice > Flashcards

E1 association practice Flashcards

1
Q

P16 or P53

A

tumor suppressor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CDK4/6 cell cycle phase

A

g1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CYP19

A

aromatase
steroidal/non-steriodal
androgens to estrogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

lymphoid lineage

A

glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

antag and agonist effects

A

tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

adipocytes

A

source of estrogen in post meno women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

6.5

A

prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

flare

A

GnRH analogs (leuprolide, goselerin)
feminization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

17-a-hydrolase and CYP17

A

Abiraterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

-lutamide

A

Androgen receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

inactive confirmation

A

type II kinase inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

t790M

A

resistance to gefitinib
use osimertinib to treat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

covalent

A

Afatinib
Osimertinib
Acalabrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mesenchymal

A

sarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

both EGFR and HER2

A

lapatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sxs of CHF

A

lapatinib, trast/pert

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

GOAL

A

EGFR inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

FLT3

A

myeloid leukemia
midostaurin
crenolanib
quizartinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

ITD mutations

A

quizartinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Philadelphia

A

Bcr-Abl
CML
Imatinib
Ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

T315, gatekeeper

A

Ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

EML4-ALK

A

wild type
alectinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

BRAF-V600

A

dabrafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Dabrafenib

A

BRAF-V600
wild type
combo with trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

trametinib

A

MEK1 and MEK2
rash
allosteric (type III)
combo with dabraf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

BTK

A

B cells
Ibrutinib
Acalabrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Cys481

A

Acalabrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

mTOR

A

rapamycin analogs
-limus drugs
serine-threonine kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

interfere with pyrimidine nucleotide synthesis

A

5-FU
capecitabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Inhibit DNA polymerase alpha

A

Cytarabine and Gemcitabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

thymidylate synthase

A

5-FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

DPD

A

5-FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Thymidine

A

5-FU rescue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

5-FU synergy

A

leucovorate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Capecitabine

A

prodrug of 5-FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Cytidine deaminase

A

Cytarabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

DNA polymerase alpha

A

Ara-CTP Cytarabine shit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

tetrahydrouridine

A

cytidine deaminase inhibitor
cytarabine combo for effiacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

block purine synthesis

A

6-MP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

TPMT

A

6-MP genetic shit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

allopurinol

A

6-MP
xanthine oxidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

6-TG

A

allopurinol does NOT block breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

DHFR

A

folic acid/folates
TMP synthesis
methotrexate

44
Q

methotrexate rescue

A

leucovorin
reverse toxic effects of DHFR inhibition

45
Q

intrastrand and interstrand

A

dna alkylation

46
Q

second malignancies

A

alkylators

47
Q

all alkylators SE

A

myelosuppression

48
Q

aryl group

A

chlorambucil
decrease nucleophilicity

49
Q

hydroxylation by CP450

A

cyclophosphamide

50
Q

aldehyde dehydrogenase

A

cyclophosphamide
acrolein

51
Q

acrolein

A

cyclophosphamide
aldehyde dehydrogenase

52
Q

hemorrhagic cystitis

A

acrolein
cyclophosphamide

53
Q

mesna

A

cyclophosphamide
bladder
urine

54
Q

bifunctional adducts

A

mitomycin C (alkylator)

55
Q

prodrug (4)

A

tamoxifen
capecitabine
irinotecan (SN38)
cyclophosphamide

56
Q

crosslinkers

A

platinum drugs
cisplatin
alkylators

57
Q

cisplatin

A

intrastrand
aquo form shit

58
Q

nephrotoxicity
ototoxicity

59
Q

increased expression resistance class glutathione-S-transferase (GST)

A

alkylating agents

60
Q

flu-like sxs with CHF risk

A

trastuzumab

61
Q

inhibit dimerization drug

A

pertuzumab

62
Q

CLEOPATRA

A

trast and pertuz
HER2+

63
Q

EGF and TGF-alpha

64
Q

CYP2d6

65
Q

severe infusion reaction

66
Q

VEGF

A

angiogenesis
bevacizumab

67
Q

CD20

A

b cells (non-hodgkins)
rituximab
Ofatumumab

68
Q

CD38

A

daratumumab

69
Q

HER2/Neu

A

trastuzumab emtansine

70
Q

CD3 and CD19

A

blinatumomab
Target T cells
also think CD3 apparently

71
Q

CD3 and CD20

A

Mosunetuzumab

72
Q

CTLA-4 and PD1 purpose

A

reactivate T cells

73
Q

bind to CTLA-4

A

Ipilimumab

73
Q

PD-1 location

A

on T cells

74
Q

bind PD-1

A

pembrolizumab

75
Q

Binds PDL-1

A

Atezolizumab

76
Q

expressed on macrophages on tumor cells

77
Q

PAP-GM-CSF

A

sipulcel-T
stimulate immune system to attack cancer

78
Q

isolates T cells

79
Q

CD19

A

target for CAR-T

80
Q

topo I cleavage

81
Q

Glutathione-s-transferase overexpression

A

resistance in topo I inhibitors

82
Q

UGT1A1

A

Irinotecan polymorphism increases toxicity

83
Q

SN-38

A

Irinotecan active metabolite

84
Q

Topo I phase

85
Q

anthracycline

A

topo II
doxorubicin

86
Q

cardiotoxicity

A

doxorubicin
free radicals
dextra drug

87
Q

G2/M block cell cycle

A

etoposide
vincristine
bleomycin

88
Q

kinectochore

A

spindle assembly
microtubule inhibitors

89
Q

peripheral neuropathy

A

vinca alkaloids

90
Q

neurotoxicity and severe local inflammation

A

vincristine
vinca

91
Q

taxane bind

A

tubulin
block depolymerization

92
Q

Poor PGP substrate

A

epothilones (ixabepilone)

93
Q

Proteasome activity

A

Bortezomib

94
Q

ubiquitin

A

bortezomib
proteasome

95
Q

potent teratogen

A

thalidomide

96
Q

cereblon

A

pomalidomide
PROTACs

97
Q

BCL-2

A

venetoclax

98
Q

intercalators

A

irinotecan
bleomycin
doxorubicin

99
Q

23% lung cancers

A

EGFR mutations

100
Q

drug enhances t cell activation

A

ipilimumab

101
Q

no requirement of chemical or enzymatic change drug

A

doxorubicin

102
Q

5-azacytidine

A

DNA methyltransferase

103
Q

BCR

A

CD20 works in combo with

104
Q

L85R mutation

105
Q

allosteric

A

trametinib

PHRM 864 (29 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions